Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call

SEATTLE, July 30, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. ONTY today announced that it will conduct a conference call on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its second quarter 2015 financial results.

To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon's website at www.oncothyreon.com. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.

About Oncothyreon

Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our current clinical-stage product candidates include ONT-380, an orally active and selective small molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting MUC1. We are developing preclinical product candidates in oncology and immuno-oncology using our protocell technology. For more information, visit www.oncothyreon.com.